Univariate analysis of the effects of patient characteristics on survival
Patient characteristics4-150 . | No. of patients . | No. of deaths . | Percentile of survival (mo) . | P(log-rank test) . | ||
---|---|---|---|---|---|---|
75% . | 50% . | 25% . | ||||
Age | ||||||
65 years or younger | 109 | 85 | 6 | 14 | 31 | NS |
Older than 65 years | 104 | 82 | 4 | 10 | 20 | |
Sex | ||||||
Female | 63 | 52 | 4 | 16 | 28 | NS |
Male | 150 | 115 | 5 | 11 | 25 | |
Prior malignancy | ||||||
No | 129 | 91 | 5 | 15 | 31 | NS |
Yes | 34 | 30 | 7 | 10 | 16 | |
AHD | ||||||
No | 58 | 54 | 6 | 14 | 26 | NS |
Yes | 151 | 109 | 5 | 11 | 27 | |
Splenomegaly | ||||||
No | 138 | 110 | 6 | 13 | 27 | NS |
Yes | 61 | 46 | 4 | 11 | 27 | |
Hemoglobin level | ||||||
Lower than 120 g/L (12 g/dL) | 168 | 134 | 4 | 10 | 20 | < .01 |
120 g/L or higher (12 g/dL) | 45 | 33 | 13 | 21 | 41 | |
Platelets count | ||||||
No higher than 50 × 109/L | 62 | 45 | 3 | 7 | 15 | < .01 |
50-100 × 109/L | 54 | 45 | 4 | 10 | 19 | |
Higher than 100 × 109/L | 93 | 74 | 8 | 19 | 33 | |
White blood cells count | ||||||
No higher than 10 × 109/L | 56 | 37 | 7 | 14 | 41 | < .01 |
Higher than 10 × 109/L | 157 | 130 | 5 | 11 | 23 | |
No higher than 13 × 109/L | 74 | 51 | 5 | 13 | 33 | .03 |
Higher than 13 × 109/L | 139 | 116 | 5 | 12 | 20 | |
Neutrophil count | ||||||
No higher than 2.5 × 109/L | 40 | 30 | 3 | 8 | 38 | NS |
Higher than 2.5 × 109/L | 165 | 130 | 5 | 12 | 23 | |
No higher than 9 × 109/L | 99 | 74 | 5 | 13 | 31 | NS |
Higher than 9 × 109/L | 106 | 86 | 5 | 11 | 20 | |
Monocyte count | ||||||
No higher than 4 × 109/L | 102 | 75 | 6 | 14 | 32 | .03 |
Higher than 4 × 109/L | 111 | 92 | 5 | 11 | 21 | |
Lymphocyte count | ||||||
No higher than 2.5 × 109/L | 75 | 46 | 7 | 18 | 37 | < .01 |
Higher than 2.5 × 109/L | 130 | 114 | 4 | 10 | 20 | |
Peripheral blood IMCs | ||||||
0% | 43 | 31 | 7 | 24 | 39 | < .01 |
More than 0% | 154 | 122 | 4 | 9 | 18 | |
LDH | ||||||
No higher than 700 U/L | 82 | 55 | 7 | 17 | 39 | < .01 |
Higher than 700 U/L | 120 | 102 | 4 | 10 | 20 | |
β2-microglobulin level4-151 | ||||||
No higher than 4 mg/L | 36 | 20 | 6 | 15 | 23 | .02 |
Higher than 4 mg/L | 28 | 20 | 4 | 6 | 11 | |
BM blasts | ||||||
Less than 5% | 115 | 89 | 7 | 17 | 28 | < .01 |
5%-10% | 56 | 43 | 5 | 10 | 27 | |
10% or more | 36 | 30 | 3 | 7 | 14 | |
BM monocytes | ||||||
No more than 20% | 137 | 104 | 5 | 12 | 26 | NS |
More than 20% | 44 | 35 | 4 | 10 | 28 | |
BM lymphocytes | ||||||
No more than 9% | 149 | 113 | 5 | 14 | 27 | NS |
More than 9% | 40 | 34 | 3 | 7 | 13 | |
BM erythroid cells | ||||||
No more than 10% | 68 | 58 | 4 | 8 | 20 | < .01 |
More than 10% | 124 | 92 | 6 | 13 | 32 | |
BM myeloid–erythroid cell ratio | ||||||
No more than 6 | 126 | 93 | 5 | 11 | 31 | .05 |
More than 6 | 66 | 57 | 4 | 11 | 20 | |
Karyotype | ||||||
Diploid | 135 | 100 | 6 | 16 | 28 | .01 |
Abnormal | 70 | 59 | 3 | 8 | 18 | |
ras point mutation‡ | ||||||
Normal | 40 | 32 | 5 | 13 | 21 | NS |
Mutation | 25 | 15 | 6 | 11 | 19 |
Patient characteristics4-150 . | No. of patients . | No. of deaths . | Percentile of survival (mo) . | P(log-rank test) . | ||
---|---|---|---|---|---|---|
75% . | 50% . | 25% . | ||||
Age | ||||||
65 years or younger | 109 | 85 | 6 | 14 | 31 | NS |
Older than 65 years | 104 | 82 | 4 | 10 | 20 | |
Sex | ||||||
Female | 63 | 52 | 4 | 16 | 28 | NS |
Male | 150 | 115 | 5 | 11 | 25 | |
Prior malignancy | ||||||
No | 129 | 91 | 5 | 15 | 31 | NS |
Yes | 34 | 30 | 7 | 10 | 16 | |
AHD | ||||||
No | 58 | 54 | 6 | 14 | 26 | NS |
Yes | 151 | 109 | 5 | 11 | 27 | |
Splenomegaly | ||||||
No | 138 | 110 | 6 | 13 | 27 | NS |
Yes | 61 | 46 | 4 | 11 | 27 | |
Hemoglobin level | ||||||
Lower than 120 g/L (12 g/dL) | 168 | 134 | 4 | 10 | 20 | < .01 |
120 g/L or higher (12 g/dL) | 45 | 33 | 13 | 21 | 41 | |
Platelets count | ||||||
No higher than 50 × 109/L | 62 | 45 | 3 | 7 | 15 | < .01 |
50-100 × 109/L | 54 | 45 | 4 | 10 | 19 | |
Higher than 100 × 109/L | 93 | 74 | 8 | 19 | 33 | |
White blood cells count | ||||||
No higher than 10 × 109/L | 56 | 37 | 7 | 14 | 41 | < .01 |
Higher than 10 × 109/L | 157 | 130 | 5 | 11 | 23 | |
No higher than 13 × 109/L | 74 | 51 | 5 | 13 | 33 | .03 |
Higher than 13 × 109/L | 139 | 116 | 5 | 12 | 20 | |
Neutrophil count | ||||||
No higher than 2.5 × 109/L | 40 | 30 | 3 | 8 | 38 | NS |
Higher than 2.5 × 109/L | 165 | 130 | 5 | 12 | 23 | |
No higher than 9 × 109/L | 99 | 74 | 5 | 13 | 31 | NS |
Higher than 9 × 109/L | 106 | 86 | 5 | 11 | 20 | |
Monocyte count | ||||||
No higher than 4 × 109/L | 102 | 75 | 6 | 14 | 32 | .03 |
Higher than 4 × 109/L | 111 | 92 | 5 | 11 | 21 | |
Lymphocyte count | ||||||
No higher than 2.5 × 109/L | 75 | 46 | 7 | 18 | 37 | < .01 |
Higher than 2.5 × 109/L | 130 | 114 | 4 | 10 | 20 | |
Peripheral blood IMCs | ||||||
0% | 43 | 31 | 7 | 24 | 39 | < .01 |
More than 0% | 154 | 122 | 4 | 9 | 18 | |
LDH | ||||||
No higher than 700 U/L | 82 | 55 | 7 | 17 | 39 | < .01 |
Higher than 700 U/L | 120 | 102 | 4 | 10 | 20 | |
β2-microglobulin level4-151 | ||||||
No higher than 4 mg/L | 36 | 20 | 6 | 15 | 23 | .02 |
Higher than 4 mg/L | 28 | 20 | 4 | 6 | 11 | |
BM blasts | ||||||
Less than 5% | 115 | 89 | 7 | 17 | 28 | < .01 |
5%-10% | 56 | 43 | 5 | 10 | 27 | |
10% or more | 36 | 30 | 3 | 7 | 14 | |
BM monocytes | ||||||
No more than 20% | 137 | 104 | 5 | 12 | 26 | NS |
More than 20% | 44 | 35 | 4 | 10 | 28 | |
BM lymphocytes | ||||||
No more than 9% | 149 | 113 | 5 | 14 | 27 | NS |
More than 9% | 40 | 34 | 3 | 7 | 13 | |
BM erythroid cells | ||||||
No more than 10% | 68 | 58 | 4 | 8 | 20 | < .01 |
More than 10% | 124 | 92 | 6 | 13 | 32 | |
BM myeloid–erythroid cell ratio | ||||||
No more than 6 | 126 | 93 | 5 | 11 | 31 | .05 |
More than 6 | 66 | 57 | 4 | 11 | 20 | |
Karyotype | ||||||
Diploid | 135 | 100 | 6 | 16 | 28 | .01 |
Abnormal | 70 | 59 | 3 | 8 | 18 | |
ras point mutation‡ | ||||||
Normal | 40 | 32 | 5 | 13 | 21 | NS |
Mutation | 25 | 15 | 6 | 11 | 19 |